Advertisement

Drug Safety

, Volume 29, Issue 1, pp 91–93 | Cite as

The Erice Declaration

The Critical Role of Communication in Drug Safety
  • Bruce Hugman
Commentary

Abstract

The Erice Declaration on Communicating Drug Safety Information, first published in September 1997, provides a vision of vigorous, open, ethical, patient-centred communications in drug safety that the world has yet to achieve. The Declaration is reprinted here as a further stimulus to all parties to renew their commitment and to add new momentum to the improvements which have undoubtedly taken place in the past few years. The content of the Declaration is briefly reviewed, and some of the continuing communications challenges and problems are outlined.

Keywords

Effective Communication Communication Challenge Communication Expert Stake Holder Flawed Behaviour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Bruce Hugman is a consultant in communications to the Uppsala Monitoring Centre, and was one of the organising team for the 1997 Erice meeting. Professor I. Ralph Edwards and Professor Giampaolo Velo share the views expressed by Bruce Hugman in this article.

References

  1. 1.
    McNamee D. Communicating drug-safety information. Lancet 1997; 350: 1646PubMedCrossRefGoogle Scholar
  2. 2.
    Scheffler AL. Safe and effective use of medications: a global concern; Qual Saf Health Care 2002; 11: 292–3CrossRefGoogle Scholar
  3. 3.
    Peart R. Procedures relating to adverse clinical incidents and outcomes in medical care. UK Parliament, evidence to the Select Committee of Health; 1999 Jun1999Google Scholar
  4. 4.
    Mills A, Edwards IR. The combined oral contraceptive pill: are poor communication systems responsible for loss of confidence in this contraceptive method? Hum Reprod 1999 Jan; 14(1): 7–10PubMedCrossRefGoogle Scholar
  5. 5.
    Balkrishnan R, Furberg CD. Developing an optimal approach to drug safety. J Intern Med 2001 Oct; 250(4): 271–9PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards IR. The WHO World Alliance for Patient Safety: a new challenge or an old one neglected? Drug Saf 2005; 28(5): 379–86PubMedCrossRefGoogle Scholar
  7. 7.
    The role of communication in patient safety and pharmacotherapy effectiveness. Agenda of the European Society of Clinical Pharmacy’s 35th Symposium; 2006 Oct 18-21; ViennaGoogle Scholar
  8. 8.
    Pharmacovigilance of herbal medicines: current and future directions (agenda items). Proceedings of Great Britain’s Royal Pharmaceutical Society Meeting; 2006 Apr 26–28; LondonGoogle Scholar
  9. 9.
    Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000 Dec 20; 284(23): 3036–9PubMedCrossRefGoogle Scholar
  10. 10.
    Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286(7): 831–3PubMedCrossRefGoogle Scholar
  11. 11.
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004 Jul 3; 329(7456): 15–9PubMedCrossRefGoogle Scholar
  12. 12.
    Improving rational drug use in Dar es Salaam, Tanzania, by elaborating and implementing Standard Treatment Guidelines (STG). Bulletin von Medicus Mundi Schweiz 1998 Marz; 68Google Scholar
  13. 13.
    Vedantam S. FDA told its analysts to censor data on antidepressants. Washington Post 2004 Sept 24; A08Google Scholar
  14. 14.
    Foggo D. ADHD advice secretly paid for by drugs companies. Daily Telegraph (UK) 2005 Oct 10Google Scholar
  15. 15.
    Boseley S. Drug safety body accused of cover up. Guardian (UK) 2004 Sat March 13Google Scholar
  16. 16.
    The Uppsala Monitoring Centre. Effective communications in pharmacovigilance; the Erice Report. Uppsala: WHO/UMC 1998Google Scholar
  17. 17.
    The Uppsala Monitoring Centre. Dialogue in pharmacovigilance: more effective communication. Uppsala: WHO/UMC 2002Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Bruce Hugman
    • 1
  1. 1.The Uppsala Monitoring CentreUppsalaSweden

Personalised recommendations